Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20; 26(33):5422-8.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Carcinoma, Renal Cell
Disease-Free Survival
Female
Humans
Interferon-alpha
Kidney Neoplasms
Male
Middle Aged
Risk Factors
Vascular Endothelial Growth Factor A

authors with profiles

Walter M. Stadler